BACKGROUND: Up to 30% of young adults with velocardiofacial syndrome (VCFS; 22q11.2 deletion syndrome) develop schizophrenia or psychosis. Identifying the neuroanatomic trajectories that increase risk for psychosis in youth with this genetic disorder is of great interest. METHODS: We acquired high-resolution anatomic magnetic resonance images and measures of psychiatric function on 72 youth with VCFS, 26 unaffected siblings, and 24 age-matched community control subjects at two time points: between late childhood (mean age 11.9 years) and mid-adolescence (mean age 15.1 years). RESULTS: With the exception of cranial gray matter and orbitofrontal prefrontal cortex, neuroanatomic trajectories in youth with VCFS were comparable to unaffected siblings and community control subjects during this developmental window. However, in youth with VCFS, longitudinal decreases in the volumes of cranial gray and white matter, prefrontal cortex, mesial temporal lobe, and cerebellum were associated with increased combined prodromal symptoms at Time 2. In contrast, only decreases in temporal lobe gray matter volumes (p < .002) and verbal IQ (p < .002) predicted specifically to positive prodromal symptoms of psychosis at Time 2. CONCLUSIONS: These findings are in line with studies of non-VCFS individuals at risk for schizophrenia and suggest that early decrements in temporal lobe gray matter may be predictive of increased risk of prodromal psychotic symptoms in youth with VCFS.
BACKGROUND: Up to 30% of young adults with velocardiofacial syndrome (VCFS; 22q11.2 deletion syndrome) develop schizophrenia or psychosis. Identifying the neuroanatomic trajectories that increase risk for psychosis in youth with this genetic disorder is of great interest. METHODS: We acquired high-resolution anatomic magnetic resonance images and measures of psychiatric function on 72 youth with VCFS, 26 unaffected siblings, and 24 age-matched community control subjects at two time points: between late childhood (mean age 11.9 years) and mid-adolescence (mean age 15.1 years). RESULTS: With the exception of cranial gray matter and orbitofrontal prefrontal cortex, neuroanatomic trajectories in youth with VCFS were comparable to unaffected siblings and community control subjects during this developmental window. However, in youth with VCFS, longitudinal decreases in the volumes of cranial gray and white matter, prefrontal cortex, mesial temporal lobe, and cerebellum were associated with increased combined prodromal symptoms at Time 2. In contrast, only decreases in temporal lobe gray matter volumes (p < .002) and verbal IQ (p < .002) predicted specifically to positive prodromal symptoms of psychosis at Time 2. CONCLUSIONS: These findings are in line with studies of non-VCFS individuals at risk for schizophrenia and suggest that early decrements in temporal lobe gray matter may be predictive of increased risk of prodromal psychotic symptoms in youth with VCFS.
Authors: J N Giedd; J Blumenthal; N O Jeffries; F X Castellanos; H Liu; A Zijdenbos; T Paus; A C Evans; J L Rapoport Journal: Nat Neurosci Date: 1999-10 Impact factor: 24.884
Authors: Linda E Campbell; Eileen Daly; Fiona Toal; Angela Stevens; Rayna Azuma; Marco Catani; Virginia Ng; Therese van Amelsvoort; Xavier Chitnis; William Cutter; Declan G M Murphy; Kieran C Murphy Journal: Brain Date: 2006-03-28 Impact factor: 13.501
Authors: W R Kates; I S Warsofsky; A Patwardhan; M T Abrams; A M Liu; S Naidu; W E Kaufmann; A L Reiss Journal: Psychiatry Res Date: 1999-07-30 Impact factor: 3.222
Authors: Heather C Strasser; Jessica Lilyestrom; Ebony R Ashby; Nancy A Honeycutt; David J Schretlen; Ann E Pulver; Ramona O Hopkins; J Raymond Depaulo; James B Potash; Barbara Schweizer; Khara O Yates; Elizabeth Kurian; Patrick E Barta; Godfrey D Pearlson Journal: Biol Psychiatry Date: 2005-03-15 Impact factor: 13.382
Authors: Ellen A A van der Plas; Aaron D Boes; John A Wemmie; Daniel Tranel; Peg Nopoulos Journal: Soc Cogn Affect Neurosci Date: 2010-02-11 Impact factor: 3.436
Authors: S M Lawrie; H Whalley; J N Kestelman; S S Abukmeil; M Byrne; A Hodges; J E Rimmington; J J Best; D G Owens; E C Johnstone Journal: Lancet Date: 1999-01-02 Impact factor: 79.321
Authors: Daqiang Sun; Lisa Phillips; Dennis Velakoulis; Alison Yung; Patrick D McGorry; Stephen J Wood; Theo G M van Erp; Paul M Thompson; Arthur W Toga; Tyrone D Cannon; Christos Pantelis Journal: Schizophr Res Date: 2009-01-12 Impact factor: 4.939
Authors: Carina Heller; Saskia Steinmann; James J Levitt; Nikos Makris; Kevin M Antshel; Wanda Fremont; Ioana L Coman; Stefan R Schweinberger; Thomas Weiß; Sylvain Bouix; Marek R Kubicki; Wendy R Kates; Zora Kikinis Journal: Schizophr Res Date: 2020-10-23 Impact factor: 4.939
Authors: Wendy R Kates; Amy K Olszewski; Matthew H Gnirke; Zora Kikinis; Joshua Nelson; Kevin M Antshel; Wanda Fremont; Petya D Radoeva; Frank A Middleton; Martha E Shenton; Ioana L Coman Journal: Schizophr Res Date: 2014-07-25 Impact factor: 4.939
Authors: Arun Kunwar; Seethalakshmi Ramanathan; Joshua Nelson; Kevin M Antshel; Wanda Fremont; Anne Marie Higgins; Robert J Shprintzen; Wendy R Kates Journal: Schizophr Res Date: 2012-02-22 Impact factor: 4.939
Authors: Matthew D Perlstein; Moeed R Chohan; Ioana L Coman; Kevin M Antshel; Wanda P Fremont; Matthew H Gnirke; Zora Kikinis; Frank A Middleton; Petya D Radoeva; Martha E Shenton; Wendy R Kates Journal: Schizophr Res Date: 2013-12-08 Impact factor: 4.939
Authors: Lucia-Manuela Cantonas; Valentina Mancini; Tonia A Rihs; Vincent Rochas; Maude Schneider; Stephan Eliez; Christoph M Michel Journal: Schizophr Bull Date: 2021-01-23 Impact factor: 9.306